Sulzer is to acquire Swiss-German privately held drug delivery device developer and manufacturer Haselmeier for an enterprise value of €100m (US$118.3m). Haselmeier is an own-IP provider of drug delivery devices such as subcutaneous self-injection pens for use in fast-growing indications such as reproductive health, growth disorders, osteoporosis and diabetes. Haselmeier employs 230 people and had…
©2023 All rights reserved LaingBuisson 
.){kind=link}